BiotechTube

LAG525 + PDR001 + Carboplatin

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple-negative Breast Cancer

Conditions

Triple-negative Breast Cancer

Trial Timeline

Jul 2, 2018 → Nov 24, 2021

NCT ID
NCT03499899

About LAG525 + PDR001 + Carboplatin

LAG525 + PDR001 + Carboplatin is a phase 2 stage product being developed by Novartis for Triple-negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03499899. Target conditions include Triple-negative Breast Cancer.

What happened to similar drugs?

1 of 7 similar drugs in Triple-negative Breast Cancer were approved

Approved (1) Terminated (0) Active (6)
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
🔄Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for IpatasertibRochePhase 3
🔄Atezolizumab + Nab-PaclitaxelRochePhase 3
🔄Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Atezolizumab Placebo + PaclitaxelRochePhase 3
🔄Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + PegfilgrastimRochePhase 3
🔄AK112 + Nab-paclitaxel + PlaceboAkesoPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03499899Phase 2Completed

Competing Products

20 competing products in Triple-negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Cisplatin + AZD1775AstraZenecaPhase 2
35
olaparib + DurvalumabAstraZenecaPhase 2
27
AZD2014 + AZD6244AstraZenecaPhase 1/2
28
OlaparibAstraZenecaPhase 1
29
Carboplatin + Docetaxel + Pembrolizumab + PegfilgrastimMerckPhase 2
39
Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
47
AN0025 + PembrolizumabMerckPhase 1
33
Pembrolizumab + AxatilimabMerckPhase 2
39
AE37 Peptide vaccine + PembrolizumabMerckPhase 2
31
Pembrolizumab + AxatilimabMerckPhase 2
42
Zilovertamab vedotinMerckPhase 2
27
Pembrolizumab + Paclitaxel + BevacizumabMerckPhase 2
42
OlinvacimabMerckPhase 2
27
Trilaciclib + Pembrolizumab + Gemcitabine + CarboplatinMerckPhase 2
39
Atezolizumab + Ipatasertib + Paclitaxel + Placebo for Atezolizumab + Placebo for IpatasertibRochePhase 3
40
Atezolizumab + Nab-PaclitaxelRochePhase 3
40
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Atezolizumab Placebo + PaclitaxelRochePhase 3
40
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody + Placebo + Nab-paclitaxel + Doxorubicin + Cyclophosphamide + Filgrastim + PegfilgrastimRochePhase 3
40
Tiragolumab + Atezolizumab + Nab-paclitaxel + Tiragolumab + Atezolizumab + Nab-paclitaxel + Carboplatin + Doxorubicin + Cyclophosphamide + Granulocyte colony-stimulating factor (G-CSF) + Granulocyte-macrophage colony-stimulating factor (GM-CSF)RochePhase 1
29